Some changes have been made to interactions with dolutegravir (Tivicay), dolutegravir/abacavir/lamivudine (Triumeq) and dolutegravir/lamivudine (Dovato) with the known enzyme/transporter inducers, rifampicin, rifapentine, carbamazepine, oxcarbazepine, eslicarbazepine, phenytoin, phenobarbitone, primidone and St John’s Wort. Summaries for these interactions have been revised and in some cases the colour coding has changed from red to amber.
Our colour coding normally reflects the most cautious regulatory position and therefore for most of the above inducers the coding to date has been red due to a ‘coadministration not recommended’ position of one of the regulatory agencies. However, there is emerging data the interaction between dolutegravir and inducers can be managed by an additional 50 mg dolutegravir tablet and we think this should be clear to health care professionals both in the colour coding (now amber) and the associated summary.
These interactions have been updated on the website checker and on the iChart app. The Prescribing Resources (Overview of Interactions and Treatment Selectors) are in the process of being updated.
